Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elite PharmaceuticalsELTP -1.49%60 Interest Coverage is 103.00 as of Jun. 2026, which is 360% above its 10-year median of 22.37. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.52 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 678 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 79.94% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Elite Pharmaceuticals's
Operating Income
for the
three
months ended in Jun. 2026 was $7.5 Mil. Elite Pharmaceuticals's Interest Expense for the
three
months ended in Jun. 2026 was $-0.1 Mil.
Elite Pharmaceuticals's interest coverage for the quarter that ended in Jun. 2026 was 103.00.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Elite Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Elite Pharmaceuticals's Interest Coverage or its related term are showing as below:
ELTP'
s Interest Coverage Range Over the Past 10 Years
Min: 3.57 Med: 22.37 Max: 125.84
Current: 115.45
ELTP's Interest Coverage is ranked better than 79.94% of 678
companies
in the Drug Manufacturers industry
Industry Median: 12.575
vs ELTP: 115.45
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Elite Pharmaceuticals Interest Coverage Related Terms
Elite Pharmaceuticals Interest Coverage Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ELTP vs EBS, ANIK, AKBA: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elite Pharmaceuticals (ELTP) has a Interest Coverage of 103.00 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Elite Pharmaceuticals and its competitors. This is 360% above median its historical median of 22.37. Over the past decade, Elite Pharmaceuticals' Interest Coverage has ranged from 3.57 to 125.84. According to the industry distribution chart, Elite Pharmaceuticals ranks #136 out of 678 companies in the Drug Manufacturers industry, placing it in the top 20.1%.
Is Elite Pharmaceuticals' Interest Coverage too high?
Elite Pharmaceuticals' current Interest Coverage of 103.00 is 360% above median its 10-year median of 22.37. Over the past 10 years, this metric has ranged from a low of 3.57 to a high of 125.84. The Drug Manufacturers industry median Interest Coverage is 12.58. Elite Pharmaceuticals' value of 103.00 is 719.1% above this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #136 out of 678 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Interest Coverage compare to EBS and ANIK?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #136 out of 678 companies for Interest Coverage. This places Elite Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.58. Elite Pharmaceuticals' value of 103.00 is 719.1% above this benchmark. Historically, Elite Pharmaceuticals' own Interest Coverage has ranged from 3.57 to 125.84 over the past decade. While the company's 10-year median is 22.37 vs. the industry median of 12.58, Elite Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.58, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current Interest Coverage of 103.00 is 719.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current Interest Coverage is 103.00, which is 360% above median its own 10-year median of 22.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.52, compared to a current price of $0.25 — trading 52.9% below its estimated fair value. The current Interest Coverage is 103.00, which is 360% above median its 10-year median of 22.37 and 719.1% above the Drug Manufacturers industry median of 12.58. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Interest Coverage is 103.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.25 is trading 52.9% below its estimated GF Value™ of $0.52.
GuruFocus considers Elite Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ELTP:
Interest Coverage: 103.00 (360% above median its 10-year median of 22.37)
GF Value™: $0.52 vs. price of $0.25 (52.9% below fair value)
Industry Position: 719.1% above the Drug Manufacturers median (#136 of 678)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score
Get the complete analysis for ELTP
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
